×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Lessons Learned in the Development and Registration of Fixed-Dose Combination Products: CMC Focus
Session Chair(s)
Chandra Vemavarapu, PhD
Associate Director
Bristol-Myers Squibb Company, United States
Hear from industry and regulatory experts on best practices for development and registration of combination products in this forum.
Learning Objective : Discuss current trends in the development of fixed-dose combination products including guidelines, challenges, and opportunities; Describe best practices in the development and registration of combination products; Influence continuous improvement in the regulatory framework around combination products.
Speaker(s)
Global Regulatory Framework and the CMC Challenges and Considerations for Fixed-Dose Combbinations
Xiling Song, MS
Genentech, A Member of the Roche Group, United States
Senior Quality Product Leader
FDA Perspective
George Lunn, PhD
FDA, United States
Chemist, ONDQA, OPS, CDER
Have an account?